Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes. Read More ›

For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed. Read More ›

After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma. Read More ›

Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival. Read More ›

Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative. Read More ›

In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials. Read More ›

Final analysis of patient-reported outcomes from the phase 3 ELOQUENT-2 trial confirms elotuzumab has no negative impact on health-related quality of life. Read More ›

In patients with relapsed/refractory multiple myeloma, treatment with elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone shows encouraging responses, with manageable toxicity. Read More ›

Compared with intravenous (IV) administration, subcutaneous daratumumab led to similar response rates with fewer infusion-related reactions. Read More ›

In systemic amyloid light chain (AL) amyloidosis, treatment with ixazomib/dexamethasone proved more beneficial than treatment of physician’s choice, although hematologic response was not improved. Read More ›